Restarting Wegovy after a break needs a different conversation from dealing with one late injection. This UK guide explains what to check in the official medicine information, which details to prepare for a prescriber and which symptoms need urgent attention. A forum post about a four-week break cannot establish another person’s restart plan.

Restarting Wegovy versus a single missed dose

The UK Wegovy patient information leaflet and the Summary of Product Characteristics (SmPC) serve different audiences. The leaflet gives patient-facing information and says that treatment should not be stopped without speaking to a doctor. It also directs people with questions to a doctor, pharmacist or nurse.

A longer interruption is not the same as one late or missed dose. The clinician-facing SmPC flags re-initiation after multiple missed doses as a matter requiring professional consideration. It does not provide a universal, self-directed answer for a particular person. That is why copying a dose mentioned in a forum thread—or simply returning to an earlier routine without review—cannot be presented as a safe general rule.

What to tell a prescriber after a Wegovy break

A prescriber or pharmacist can take account of the length of the interruption, previous tolerability, current symptoms, other medicines, relevant health conditions and the plan originally supplied. The aim is not to judge why the break happened. It is to make sure the next conversation uses accurate, current information rather than assumptions.

  • Confirm how long the interruption has lasted.
  • Describe any previous or current side effects accurately.
  • Have the medicine name, strength and original plan available.
  • Ask which current leaflet or written instruction applies.

Current MHRA safety advice still applies

The Medicines and Healthcare products Regulatory Agency (MHRA) keeps GLP-1 medicine guidance under review. Its current advice says severe, persistent stomach pain that may spread to the back, with or without nausea and vomiting, needs urgent medical attention because it can be a sign of acute pancreatitis. Sudden loss of vision or rapidly worsening eyesight while taking semaglutide also needs urgent assessment. Suspected adverse reactions can be reported through the Yellow Card scheme.

What online communities can—and cannot—do

Community discussions can help people organise questions, compare the practical experience of seeking support and feel less isolated. They cannot verify another person’s medical history, prescription or risk factors. A responsible post should therefore point back to the official leaflet and the prescribing team instead of turning one anecdote into instructions.

The responsible next step

This article is general education, not personal medical advice, prescribing or a restart schedule. For treatment decisions, use the current product information supplied with the medicine and contact the relevant prescriber, pharmacist or nurse.

Explore research-use product literacy at sveltalabs.com. Share general questions and experiences at community.sveltalabs.com.

Related reading

Explore switching from Mounjaro to Wegovy, Mounjaro restart questions.

Sources

Wegovy UK product information — https://www.medicines.org.uk/emc/product/13801/smpc

MHRA: GLP-1 medicines — https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know